Mangoceuticals and Nuclea Energy Mutually Terminate Reverse Merger Agreement
MGRX has more than doubled off its 52-week low of $0.162 on light trading volume (0.1× avg).
Summary
Mangoceuticals and Nuclea Energy mutually terminated their business combination agreement after failing to raise the required $15 million PIPE financing. The reverse merger is off, leaving Mangoceuticals with severe cash constraints and Nasdaq delisting risk.
Key Events · M&A and Partnerships · MGRX
-
Reverse Merger Terminated
Mangoceuticals and Nuclea Energy mutually terminated the Business Combination Agreement dated July 29, 2026, effective August 19, 2026.
-
PIPE Financing Failure
The termination was triggered by the inability to raise the $15 million PIPE Minimum Amount by the August 21, 2026 outside date.
-
Standalone Financial Distress
Mangoceuticals now faces a going concern warning with only $229K in cash as of Q2 2026 and Nasdaq delisting risk.
-
Mutual Releases Executed
The parties exchanged mutual releases of all claims relating to the BCA, except for willful breaches occurring prior to termination.
Analysis · MGRX · Industrial Applications And Services
The reverse merger with Nuclea Energy, which would have left existing Mangoceuticals shareholders with only 4% of the combined company, has been terminated. The deal collapsed because the required $15 million PIPE financing could not be raised by the August 21, 2026 outside date. This leaves Mangoceuticals as a standalone company with just $229K in cash, a going concern warning, and Nasdaq delisting risk. The termination removes the potential value transfer to Nuclea shareholders but also eliminates the only near-term path to a transformative transaction. The company now faces urgent capital needs and must find alternative financing or strategic options.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 40.5% of the 331 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGRX was trading at $0.40 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $9.1M. The 52-week trading range was $0.16 to $2.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.